Codiak BioSciences (CDAK) director Gillis bought 5,000,000 shares
Insider transactions reported
Steven Gillis (director at Codiak BioSciences Inc., CDAK) reported that they bought 5,000,000 shares on Sep 13, 2022. After these transactions the filing shows 7,503,903 shares held indirectly (See footnotes).
- Reporting person
- Gillis Steven
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Sep 13, 2022 | Open-market purchase (P) | Common Stock1, 2, 3 | +5,000,000 | - | - | 7,503,903 indirect |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Sep 13, 2022 | Open-market purchase (P) | Warrant (Right to Buy)On 5,000,000 Common Stock1, 2, 3 | +5,000,000 | - | - | 5,000,000 indirect |
Holdings before and after
- Common Stock: 2,503,903 to 7,503,903 indirect, See footnotes
- Warrant (Right to Buy): 0 to 5,000,000 indirect, See footnotes
Other positions listed
- Common Stock: 10,250 direct
Footnotes from the filing
- 1. Shares purchased in a private investment in public equity transaction on September 13, 2022. Accompanying the Common Stock is one Series A Warrant to purchase one share of common stock at an exercise price of $1.875 per share.
- 2. Shares and warrants held by ARCH Venture Fund VIII, L.P. ( ARCH Fund VIII ). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ( ARCH Partners VIII ), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ( ARCH VIII LLC ), which may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares and warrants held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein.
- 3. The Reporting Person is a managing director at ARCH Partners VIII and owns an interest in ARCH Partners VIII but does not have voting or investment control over the shares and warrants held by ARCH Fund VIII. The Reporting Person disclaims beneficial ownership of such shares and warrants, except to the extent of any pecuniary interest therein.
Transaction codes in this filing
- Open-market purchase:
- Code P marks a purchase in the open market or a private deal. The insider paid for these securities.
FAQ
What did Gillis report in this CDAK Form 4?
Steven Gillis (director at Codiak BioSciences Inc., CDAK) reported that they bought 5,000,000 shares on Sep 13, 2022. After these transactions the filing shows 7,503,903 shares held indirectly (See footnotes).
How many CDAK shares does Gillis hold after this filing?
The filing shows 7,503,903 shares held indirectly (See footnotes) after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code P mean on an SEC Form 4?
Code P marks a purchase in the open market or a private deal. The insider paid for these securities.
Historical context for CDAK
Earlier insider filings at CDAK
- Sep 15, 2022SEC Form 4: Arch Venture Fund Viii, L.P. bought $7,500,000 worth of Common Sotck (5,000,000 units at $1.50)
- Jun 21, 2022SEC Form 4 filed by Haddock Jason
- Jun 21, 2022SEC Form 4 filed by Bernstein Karen
- Jun 21, 2022SEC Form 4 filed by Eggimann Anne-Virginie
- Jun 21, 2022SEC Form 4 filed by Melas Kyriazi Theo
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medicinal Chemicals and Botanical Products
- Listed since
- 2020
Follow CDAK and get a push notification the moment its next story breaks.